GlobeNewsWire
25 Feb 2026, 21:01 UTC · 37w ago
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Impact · against what's priced in
Carlsmed's strong FY2025 results demonstrate rapid scaling and significant clinical validation, which should act as a positive catalyst. The 86% year-over-year revenue growth and the 74% reduction in revision rates provide a strong fundamental basis for valuation expansion.
- CARL+0.70
No priced-in read yet
- In context
The company achieved 86% full-year revenue growth to $50.5 million and expanded Q4 gross margins to 76.5%. Furthermore, clinical data showing a 74% reduction in revision rates at two years for aprevo lumbar patients provides a significant competitive advantage in patient outcomes.
Read from the article alone

Search tags




